Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Immunotherapy. University of Texas M. D. Anderson Cancer Center, Houston, TX, United States

Survival: 21.1 months
Toxicity Grade: 3
Treatments: Immunotherapy
Country: United States
City/State/Province: Houston, TX
Hospital: University of Texas M. D. Anderson Cancer Center
Journal: Link
Date: 7/2008

Patients: This phase II study involved 44 patients with metastatic renal cell carcinoma (kidney cancer). The median age was 64 years, and the majority (64%) of patients were men.

Treatment: Patients were treated with talactoferrin, an immunotherapy.

Toxicities: There was one report of grade 3 dyspnea. Other toxicities were grade 1 or 2, and included fatigue, flatulence, abdominal pain, and diarrhea.

Results: The median overall survival was 21.1 months.

Support: This study was supported by reseach funds from Agennix, Inc., which developed/owns talactoferrin.

Correspondence: Dr. Eric Jonasch

E-mail to a Friend Email Physician More Information